Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Central Hospital, Nancy, France
Since few years, therapy by 177Lu-PSMA in nancy hospital began. A lot's of datas were collected. Prostate cancer is the number one killer in france and this is very important to find a diagnostic tool.
The hypothesis of this study is to demonstrate the prognostic value of using post-therapy 177Lu-PSMA SPECT/CT versus 68Ga-PSMA-11 PET/CT in mCPRC patients progressing despite chemotherapy and treated with 177Lu-PSMA.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
patient who received a dose of 177lu-PSMA
patient who had imaging by 68Ga-PSMA
patient treated in Nancy hospital for its cancer prostate
You may not be if
no social security
no acceptation to participating in retrospective study
Clareo Health | Comparison of Changes in Tumor Burden in 68Ga-PSMA-11 PET/CT and 177Lu-PSMA SPECT/CT in Metastatic Castration-resistant Prostate Cancer
